Companies / Infinity Pharmaceuticals, Inc.
Infinity Pharmaceuticals, Inc.
INFICIK 1113148
Activity
InsidersInstitutions
What the company's own insiders are buying and selling.| Date | Actor | Action | Security | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|---|
| Jan 22, 2021 | Bvf Partners L P/IL 10% owner | Sell Open-market sale | Common Stock, $0.001 par value | $11.68M | -2.8M -33.25% | 5,663,912 | high |
| Jan 22, 2021 | Bvf Partners L P/IL 10% owner | Sell Open-market sale | Common Stock, $0.001 par value | $10.18M | -2.5M -37.08% | 4,172,298 | medium |
| Feb 11, 2021 | Bvf Partners L P/IL 10% owner | Sell Open-market sale | Common Stock, $0.001 par value | $6.53M | -1.2M -21.46% | 4,448,421 | medium |
| Feb 11, 2021 | Bvf Partners L P/IL 10% owner | Sell Open-market sale | Common Stock, $0.001 par value | $4.79M | -892K -21.39% | 3,279,831 | medium |
| Jan 22, 2021 | Bvf Partners L P/IL 10% owner | Sell Open-market sale | Common Stock, $0.001 par value | $2.35M | -568K -45.26% | 686,974 | medium |
| Feb 11, 2021 | Bvf Partners L P/IL 10% owner | Sell Open-market sale | Common Stock, $0.001 par value | $816.7K | -152K -22.14% | 534,847 | medium |
| Jun 16, 2022 | Evnin Anthony B Director | Grant Grant or award | Common Stock | $31.5K | +46K +27.44% | 215,403 | low |
| Sep 12, 2023 | Perkins Adelene Q CEO | Sell Open-market sale | Common Stock | $28.7K | -410K -25.87% | 1,175,291 | low |